Celecoxib: Uses, Side Effects, and Safe Taking Tips
Celecoxib is a prescription pain-relieving medicine known as a COX-2 inhibitor. It is used to reduce pain and inflammation from conditions such as arthritis, menstrual cramps, and certain short-term painful conditions.
Take celecoxib only as prescribed, at the lowest effective dose for the shortest needed time. Contact a doctor or pharmacist promptly for signs of serious stomach, heart, kidney, allergic, or skin reactions.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- M01AH01
- Generic
- Celecoxib
- Class
- cox2-inhibitor
- Brands
- Celebrex
- Availability
- rx
- Pregnancy
- C
- Lactation
- caution
- Half-life (h)
- 11
- Onset (min)
- 60
- Duration (h)
- 12
- Routes
- oral
- Forms
- capsule
- Regions
- CN, US, EU, JP
- Monitoring
- cardiovascular, blood-pressure, gastrointestinal
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 200mg once daily or 100mg twice daily
- Maximum
- consult physician
- Frequency
- once daily or every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 100mg twice daily (for patients 2 years and older weighing 50kg or more)
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 100mg once daily or 100mg twice daily
- Maximum
- consult physician
- Frequency
- once daily or every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks; data limited
regular fetal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimestercontraindicated
do not use in third trimester
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingavoid or discontinue breastfeeding
celecoxib is excreted in breast milk; consider alternatives or discontinue breastfeeding
monitor infant for adverse effects
Use with caution and monitor for adverse effects.
geriatric
elderly 65 yearsstart at lowest effective dose
use with caution; increased risk of GI bleeding, renal impairment, and cardiovascular events
regular monitoring of renal function, blood pressure, and for signs of bleeding
Use with caution and monitor for adverse effects.
pediatric_age
children under 18not recommended
not approved for use in pediatric patients; limited safety and efficacy data
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
moderate renal impairmentreduce dose; monitor closely
use with caution; NSAIDs may worsen renal function; avoid in severe renal impairment
monitor renal function regularly (creatinine clearance, BUN)
Use with caution and monitor for adverse effects.
renal_impairment
severe renal impairmentavoid
contraindicated in severe renal impairment
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
hepatic_impairment
moderate hepatic impairmentreduce dose to half
use with caution; may require dose reduction; monitor liver function
regular monitoring of liver function tests
Use with caution and monitor for adverse effects.
hepatic_impairment
severe hepatic impairmentcontraindicated
do not use in severe hepatic impairment
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
Statistics and clinical data
Drug class
Celecoxib belongs to the coxib class of NSAIDs that selectively inhibits cyclooxygenase-2
FDA approval year
Celecoxib was first approved by the FDA in December 1998
Commonly prescribed since
General information about medication introduction and continued use
Primary indications
Main therapeutic uses of celecoxib
Drug interactions
6 documented interaction(s) with other medications in this knowledge base.
Celecoxib作为CYP2C9抑制剂，可减少Glibenclamide的代谢，导致其血药浓度升高，增强降糖作用
塞来昔布为中度CYP2D6抑制剂，可减少羟氯喹代谢，升高其血药浓度，增加QT间期延长、视网膜病变及心肌病等毒性风险
NSAIDs（包括COX-2抑制剂）可能通过抑制内源性前列腺素合成而拮抗前列腺素类似物的降眼压作用，从而减弱latanoprost增加葡萄膜巩膜外流的疗效
Liraglutide的胃肠道不良反应可导致脱水/容量不足，从而增强Celecoxib（COX-2抑制剂）对肾前列腺素的抑制，增加急性肾损伤风险
NSAIDs（包括COX-2抑制剂）可通过抑制前列腺素减少肾血流量/GFR，并竞争肾小管分泌，从而降低甲氨蝶呤肾清除率，升高其血药浓度并增加毒性风险（骨髓抑制、黏膜炎、肝肾毒性）。Celecoxib对低剂量MTX的药代动力学影响相对较小，但仍属同类风险。
两者均可增加血栓形成风险（COX-2抑制剂抑制前列环素产生促血栓效应；复方口服避孕药升高凝血因子并降低抗凝血酶），合用可能产生叠加的静脉/动脉血栓栓塞风险
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 22, 2026. · Read our editorial policy